Scientists at Oslo University Hospital (Norway) have developed a new chimeric antigen receptor (CAR) targeting STEAP1 positive cells. STEAP1 is expressed in about 90% of prostate cancers, and subgroups of other malignancies, and it is an attractive target as it is associated with tumor invasiveness and progression, and apart from the non-vital prostate gland, only expressed at low levels in normal tissue. The scientific group has accomplished preclinical validation experiments and demonstrated in vivo efficacy in a mouse model.
Inven2 AS seeks out-licensing of the IP or partners for entering clinical phase I.
The scientific group are also developing p95HER2 CARs for metastatic breast cancer.
The in vivo activity of the CAR T cells was evaluated in a xenograft mouse model of prostate cancer. Here, the STEAP1 CAR T cells significantly inhibited tumor growth and extended survival. The T cells expanded and infiltrated the tumor in anti-STEAP1 CAR T treated mice, but not in mice treated with control T cells.
The STEAP1 CAR exhibits potent in vitro and in vivo functionality, and it can be further developed towards potential clinical use.
A patent application has been filed.